AVDL Avadel Pharmaceuticals plc

9.28
0  -1%
Previous Close 9.35
Open 9.43
Price To book 9.19
Market Cap 384.00M
Shares 41,379,000
Volume 424,161
Short Ratio 2.58
Av. Daily Volume 128,042

SEC filingsSee all SEC filings

  1. 8-K - Current report 17766659
  2. 8-K - Current report 17750504
  3. 8-K - Current report 17731247
  4. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17719900
  5. 8-K - Current report 17695660

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved June 3, 2013.
Bloxiverz (neostigmine methylsulfate)
Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery
Announced approval May 2 2016
Akovaz
Hypotension
Phase 3 SPA agreed on - October 2016. Initiation of dosing announced December 16, 2016.
Micropump Sodium Oxybate
Excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy
Approved June 30 2014.
VAZCULEP (phenylephrine hydrochloride)
Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia
Approved Jun 3 2013
Bloxiverz (neostigmine methylsulfate)
Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery

SEC Filings

  1. 8-K - Current report 17766659
  2. 8-K - Current report 17750504
  3. 8-K - Current report 17731247
  4. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17719900
  5. 8-K - Current report 17695660
  6. NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 17694560
  7. 8-K - Current report 17672016
  8. 8-K - Current report 17669591
  9. 8-K - Current report 17657219
  10. 8-K - Current report 17616408